carvedilol has been researched along with nifedipine in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.23) | 18.7374 |
| 1990's | 9 (29.03) | 18.2507 |
| 2000's | 14 (45.16) | 29.6817 |
| 2010's | 7 (22.58) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Keserü, GM | 1 |
| Du, LP; Li, MY; Tsai, KC; Xia, L; You, QD | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Jia, L; Sun, H | 1 |
| He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Sun, Y; Yan, Z | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Sen, S; Sinha, N | 1 |
| Bakmiwewa, SM; Ball, HJ; Fatokun, AA; Hunt, NH; Payne, RJ; Tran, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bennis, K; Ducki, S; Lesage, F; Vivier, D | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Derr, I; Eberhardt, R; Ehmer, B; van der Does, R | 1 |
| de Vries Robles, P; Juttmann, JR; Venuti, RP | 1 |
| Adezati, L; Albergati, F; Boeri, D; Lombardo, I; Paternó, E; Semino, S; Venuti, RP; Viviani, GL | 1 |
| Ball, SG; Dixon, S; Hall, S; Hallman, RJ; Harvey, RE; Prescott, RI | 1 |
| Derr, I; Eberhardt, R; Ehmer, B; Rudorf, J; Uberbacher, HJ; van der Does, R | 1 |
| Hoffmeister, HM; Ickrath, O; Karsch, KR; Mauser, M; Voelker, W | 1 |
| Dantas, M; Freitas, AF; Furtado, MR; Kohlmann, NE; Kohlmann, O; Plavnik, FL; Portela, JE; Spritzer, N; Spritzer, T | 1 |
| Arleth, AJ; Ohlstein, EH; Sung, CP | 1 |
| Sullivan, JM | 1 |
| Feuerstein, GZ; Fisher, M; Nunnart, J; Ruffolo, RR | 1 |
| Hobara, N; Hokama, N; Kameya, H; Ohshiro, S; Sakai, M; Sakanashi, M | 1 |
| Antonello, A; Calò, L; Davis, PA; Giacon, B; Huber, W; Pagnin, E; Piccin, A; Riegler, P; Semplicini, A | 1 |
| Iida, H; Iwasawa, K; Jo, T; Ma, J; Nagai, R; Nakajima, T; Omata, M | 1 |
| Angeli, P; Boccagni, P; Burra, P; Carraro, A; Cillo, U; Fagiuoli, S; Fasolato, S; Galioto, A; Gatta, A; Guarda, S; Sartori, M; Semplicini, A; Sticca, A; Zanus, G | 1 |
| Angeli, P; Boccagni, P; Cillo, U; Fasolato, S; Frigo, AC; Galioto, A; Gatta, A; Semplicini, A; Sticca, A; Zanus, G | 1 |
3 review(s) available for carvedilol and nifedipine
| Article | Year |
|---|---|
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
Topics: Arrhythmias, Cardiac; Depression; Epilepsy; Humans; Inflammation; Models, Molecular; Molecular Structure; Neuroprotective Agents; Pain; Potassium Channels, Tandem Pore Domain; Structure-Activity Relationship | 2016 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
A 1996 update on antihypertensive agents.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Calcium Channel Blockers; Carbazoles; Carvedilol; Diuretics; Endothelins; Humans; Hypertension; Neprilysin; Nifedipine; Propanolamines | 1996 |
10 trial(s) available for carvedilol and nifedipine
| Article | Year |
|---|---|
Efficacy and safety of carvedilol in comparison with nifedipine sustained-release in chronic stable angina.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Antihypertensive Agents; Carbazoles; Carvedilol; Delayed-Action Preparations; Double-Blind Method; Exercise Test; Humans; Male; Middle Aged; Nifedipine; Nitroglycerin; Propanolamines; Vasodilator Agents | 1992 |
Safety of the coadministration of carvedilol and nifedipine sustained-release in the treatment of essential hypertension.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Delayed-Action Preparations; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Nifedipine; Propanolamines | 1992 |
Comparison of the effects of carvedilol and nifedipine in patients with essential hypertension and non-insulin-dependent diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Heart Rate; Humans; Hypertension; Male; Middle Aged; Nifedipine; Propanolamines; Vasodilator Agents | 1992 |
A comparative study of carvedilol, slow-release nifedipine, and atenolol in the management of essential hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Carbazoles; Carvedilol; Delayed-Action Preparations; Electrocardiography; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Nifedipine; Propanolamines; Vasodilator Agents | 1991 |
Treatment of chronic stable angina with carvedilol in comparison with nifedipine s.r.
Topics: Adult; Aged; Angina Pectoris; Carbazoles; Carvedilol; Chronic Disease; Delayed-Action Preparations; Double-Blind Method; Exercise Test; Female; Humans; Male; Middle Aged; Nifedipine; Propanolamines; Vasodilator Agents | 1991 |
[The acute hemodynamic effects of the new vasodilating beta blocker carvedilol in comparison with combined administration of nifedipine and propranolol in patients with coronary heart disease].
Topics: Carbazoles; Carvedilol; Coronary Circulation; Coronary Disease; Drug Therapy, Combination; Female; Hemodynamics; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Nifedipine; Propanolamines; Propranolol; Vasodilator Agents | 1989 |
[Use of carvedilol compared to nifedipine in the treatment of mild and moderate essential arterial hypertension].
Topics: Aged; Analysis of Variance; Antihypertensive Agents; Carbazoles; Carvedilol; Clinical Protocols; Delayed-Action Preparations; Double-Blind Method; Heart Rate; Humans; Hypertension; Middle Aged; Nifedipine; Propanolamines | 1994 |
Oxidative stress and TGFbeta in kidney-transplanted patients with cyclosporin-induced hypertension. Effect of carvedilol and nifedipine.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Carbazoles; Carvedilol; Cyclosporine; Drug Evaluation; Female; Heme Oxygenase (Decyclizing); Heme Oxygenase-1; Humans; Hypertension; Immunosuppressive Agents; Kidney Transplantation; Male; Membrane Proteins; Middle Aged; Nifedipine; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Oxidative Stress; Postoperative Complications; Propanolamines; RNA, Messenger; Signal Transduction; Transforming Growth Factor beta; Treatment Outcome; Tyrosine | 2002 |
Comparison between nifedipine and carvedilol in the treatment of de novo arterial hypertension after liver transplantation: preliminary results of a controlled clinical trial.
Topics: Blood Pressure; Carbazoles; Carvedilol; Female; Heart Rate; Humans; Hypertension; Liver Transplantation; Male; Middle Aged; Nifedipine; Propanolamines; Treatment Outcome; Vasodilator Agents | 2005 |
Nifedipine versus carvedilol in the treatment of de novo arterial hypertension after liver transplantation: results of a controlled clinical trial.
Topics: Adrenergic beta-Antagonists; Calcium Channel Blockers; Carbazoles; Carvedilol; Drug Therapy, Combination; Female; Humans; Hypertension; Immunosuppression Therapy; Kidney Function Tests; Liver Transplantation; Male; Middle Aged; Nifedipine; Propanolamines; Prospective Studies; Time Factors; Treatment Outcome | 2008 |
18 other study(ies) available for carvedilol and nifedipine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
Topics: Anti-Arrhythmia Agents; Models, Biological; Models, Molecular; Potassium Channel Blockers; Potassium Channels; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2004 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
Topics: Computational Biology; Drug Discovery; Hepatocytes; Humans; Hydrogen-Ion Concentration; Liver; Metabolic Clearance Rate; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship; Sensitivity and Specificity; Software | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
Topics: Animals; Dose-Response Relationship, Drug; Enzyme Inhibitors; HEK293 Cells; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Mice; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Substrate Specificity | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Carvedilol inhibits vascular smooth muscle cell proliferation.
Topics: Adrenergic beta-Antagonists; Animals; Aorta, Thoracic; Carbazoles; Carvedilol; Cell Division; DNA; Endothelins; In Vitro Techniques; Male; Mitogens; Muscle, Smooth, Vascular; Nifedipine; Propanolamines; Prostaglandins F; Rats; Rats, Sprague-Dawley; Thymidine | 1993 |
Carvedilol inhibits aortic lipid deposition in the hypercholesterolemic rat.
Topics: Adrenergic beta-Antagonists; Animals; Aorta, Thoracic; Arteriosclerosis; Calcium Channel Blockers; Carbazoles; Carvedilol; Hypercholesterolemia; Lipid Metabolism; Male; Nifedipine; Propanolamines; Rats; Rats, Wistar; Vasodilator Agents | 1997 |
Influence of nicardipine and nifedipine on plasma carvedilol disposition after oral administration in rats.
Topics: Administration, Oral; Animals; Area Under Curve; Calcium Channel Blockers; Carbazoles; Carvedilol; Chromatography, High Pressure Liquid; Drug Interactions; Male; Nicardipine; Nifedipine; Propanolamines; Rats; Rats, Sprague-Dawley; Time Factors | 2002 |
Inhibitory effects of carvedilol on calcium channels in vascular smooth muscle cells.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Aorta; Calcium; Calcium Channels; Calcium Signaling; Carbazoles; Carvedilol; Cell Division; Endothelin-1; Metoprolol; Muscle, Smooth, Vascular; Nicardipine; Nifedipine; Propanolamines; Rats; Vasodilator Agents; Vasopressins | 2003 |